stoxline Quote Chart Rank Option Currency Glossary
  
Sintx Technologies, Inc. (SINT)
2.68  -0.01 (-0.37%)    04-10 16:00
Open: 2.655
High: 2.72
Volume: 12,607
  
Pre. Close: 2.69
Low: 2.65
Market Cap: 7(M)
Technical analysis
2026-04-10 4:39:41 PM
Short term     
Mid term     
Targets 6-month :  3.46 1-year :  4.05
Resists First :  2.97 Second :  3.46
Pivot price 2.53
Supports First :  2.52 Second :  2.25
MAs MA(5) :  2.65 MA(20) :  2.58
MA(100) :  3.22 MA(250) :  3.26
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  74.5 D(3) :  68.6
RSI RSI(14): 50.8
52-week High :  6.78 Low :  1.71
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SINT ] has closed below upper band by 20.3%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.72 - 2.74 2.74 - 2.75
Low: 2.61 - 2.63 2.63 - 2.65
Close: 2.65 - 2.68 2.68 - 2.7
Company Description

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

Headline News

Mon, 23 Mar 2026
SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution - Ortho Spine News

Mon, 23 Mar 2026
After its first human foot implant, SINTX shifts to 2026 rollout - Stock Titan

Thu, 19 Mar 2026
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant - Orthopedics This Week

Thu, 19 Mar 2026
A new foot implant reaches its first patient after FDA clearance - Stock Titan

Mon, 02 Mar 2026
SINTX Technologies names Ryan Elmore President to drive commercial expansion of SiN biomaterials - VoxelMatters

Thu, 29 Jan 2026
Silicon-nitride medtech SINTX targets investors at Noble virtual event - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 4 (M)
Shares Float 3 (M)
Held by Insiders 16.2 (%)
Held by Institutions 7.1 (%)
Shares Short 212 (K)
Shares Short P.Month 204 (K)
Stock Financials
EPS -6.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.74
Profit Margin 0 %
Operating Margin -787.6 %
Return on Assets (ttm) -69.9 %
Return on Equity (ttm) -303.8 %
Qtrly Rev. Growth -46.5 %
Gross Profit (p.s.) 0.11
Sales Per Share 0.24
EBITDA (p.s.) -2.49
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.44
PEG Ratio 0
Price to Book value 3.62
Price to Sales 10.82
Price to Cash Flow -1.29
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android